Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2016-01-05
Original SEC Filing: Click here

---

Webplus: SVA/20160105/6-K/2_EX-99.1/000.htm SEC Original: v428191_ex99-1.htm
Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING, December 10, 2015 — Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or “sIPV”) candidate. In preparation of beginning human clinical trials, Sinovac is currently finalizing the clinical

---

---

Webplus: SVA/20160105/6-K/3_EX-99.2/000.htm SEC Original: v428191_ex99-2.htm
Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine BEIJING, January 4, 2016–Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration (CFDA) issued the new drug certificate and production license for its Enterovirus 71 (“EV71”) vaccine. As previously announced, the CFDA completed its Good Manufacturing Practices

---

---

Webplus: SVA/20160105/6-K/1/000.htm SEC Original: v428191_6k.htm
FORM 6-K ————– ———- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. 6-K 1 v428191_6k.htm FORM 6-K

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2016-01-05CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085